Canada - Français
Prof. Stephen Chia (Canada) and Dr. Mark Verrill (UK) discuss the initial RxPONDER results presented at SABCS 2020 and what impact this has on the clinical practice.
TAILORx was independently led by ECOG-ACRIN Cancer Research Group with sponsorship from the National Cancer Institute. Participating cancer research groups included the Alliance for Clinical Trials in Oncology, NCIC-Clinical Trials Group, NRG Oncology, and SWOG.
The TAILORx trial followed over 10,000 women with early breast cancer for an average of 9 years. Over 1,000 trial sites in 6 countries participated.
NIH = National Institute of Health
RS = Recurrence Score result
TAILORx = A Clinical Trial Assigning IndividuaLized Options for Treatment (Rx)
The TAILORx trial was conducted independently by the ECOG-ACRIN Cancer Research Group.